Non-anti-D antibodies in red-cell alloimmunization

Area of Science:

• Obstetrics and Gynecology
• Neonatology
• Immunology

Background:

• Alloimmunization to irregular anti-red-cell antibodies poses risks to fetal and neonatal outcomes.
• Hemolytic disease of the newborn (HDN) is a significant concern in pregnancies with maternal alloimmunization.
• Management guidelines are often based on limited anecdotal evidence, particularly for severe HDN cases.

Purpose of the Study:

• To review fetal/neonatal outcomes and management strategies for pregnancies complicated by alloimmunization to irregular anti-red-cell antibodies.
• To assess the current landscape of antibody prevalence and intervention guidelines.
• To highlight specific considerations for managing Kell alloimmunization.

Main Methods:

• Comprehensive computerized MEDLINE search.
• Keywords included "hemolytic disease of the newborn" (HDN) and specific anti-red-cell antibodies like "anti-Kell antibody."
• Review of existing literature on prevalence, outcomes, and management.

Main Results:

• A decrease in anti-RhD antibody incidence was observed.
• An increasing trend of anti-K1 antibody incidence was noted in the US.
• Limited guidelines exist due to anecdotal reporting favoring severe HDN cases.

Conclusions:

• DNA techniques on amniotic fluid can exclude antigen-negative fetuses in cases of Kell, M, Duffy, and Kidd alloimmunization.
• Kell (K1 and K2) alloimmunization necessitates different management than RhD due to its potent suppression of fetal erythropoiesis.